Formycon Expands European Footprint for Aflibercept Biosimilar FYB203 with Horus Pharma Deal
Formycon announced that Klinge Biopharma, the exclusive global commercialization rights holder for Formycon’s Eylea biosimilar FYB203 (aflibercept), has entered into a new semi-exclusive license agreement with Horus Pharma. The deal grants Horus the right to commercialize the product—marketed as Baiama—in select European countries.
This agreement builds on the January 2025 partnership between Klinge and Teva Pharmaceuticals International, which secured Teva’s commercialization of FYB203 under the brand name Ahzantive across most of Europe and Israel.
While specific terms of the deal were not disclosed, Klinge will receive upfront and milestone payments, plus royalties on net sales. Formycon will share in these revenues, participating in the mid–single-digit to low–double-digit percentage range of all payment streams, according to Fornycon.
In addition, Formycon will serve as Klinge’s authorized designee to manage the FYB203 supply chain, earning service payments and a volume-based profit component.
“We are very pleased to add Horus Pharma, a distinguished specialist in ophthalmology, to our network of commercial partners," said Nicola Mikulcik, Chief Business Officer of Formycon. "With Baiama marketed alongside Ahzantive, we can achieve the best possible therapeutic coverage and fully leverage the high market potential in Europe.”
The two-brand strategy allows Teva and Horus to market the same biosimilar under different labels—Ahzantive and Baiama.
Through this agreement, Horus will market Baiama in selected European countries, including its home market of France, complementing Teva’s broader European launch of Ahzantive.
FYB203 has rapidly secured global regulatory approvals:
US FDA: Approved in June 2024
European Commission: Authorized in January 2025 under the brand names Ahzantive and Baiama
UK MHRA: Marketing authorization granted in February 2025